Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ethical Dilemmas I

Ethical Dilemmas I

Ethical dilemmas in nursing are of utmost importance, as they often arise from the tension between adhering to core ethical principles and the practical realities of healthcare delivery. These dilemmas require nurses to navigate complex situations where competing ethical considerations pull them in different directions.
Let us explore some examples to understand the potentially complex moral decisions nurses face.
Take the case of caring for minors, particularly in areas related to reproductive...

Ethical Dilemmas II

Ethical Dilemmas II

Resolving an ethical dilemma in healthcare involves a systematic approach that considers every aspect of the issue, respecting both the patient's needs and values and the healthcare professional's ethical obligations. Here are potential steps to resolve an ethical dilemma:

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reversible Orbital Apex Syndrome.

Journal of eye movement research·2026

Same author

Reply.

Cornea·2024

Same author

Tomographic Predictors of Ectasia Development After Keratorefractive Surgery.

Cornea·2024

Same author

Variants in the WDR45 Gene Within the OPA-2 Locus Associate With Isolated X-Linked Optic Atrophy.

Investigative ophthalmology & visual science·2023

Same author

Emergent cerebral venous stenting: A valid treatment option for fulminant idiopathic intracranial hypertension.

Journal of the neurological sciences·2023

Same author

[OPTIC NEURITIS - CLASSIFICATION, MANAGEMENT AND TREATMENT].

Harefuah·2022

Search research articles

Related Experiment Video

Updated: Jan 29, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

[TREATMENT DILEMMAS IN FULMINANT INTRACRANIAL HYPERTENSION].

Eyal Aloni¹, Majd Arow¹, Moris Harstein²

¹Department of Ophthalmology, Barzilai University Medical Center, Israel.

|February 20, 2019

Summary

This summary is machine-generated.

Fulminant idiopathic intracranial hypertension can cause rapid blindness. Urgent optic nerve fenestration in this case prevented further vision loss, highlighting the need for prompt recognition and treatment.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

Related Experiment Videos

Last Updated: Jan 29, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

Area of Science:

Neurology
Ophthalmology

Background:

Fulminant intracranial hypertension is a rare, acute presentation of idiopathic intracranial hypertension.
It is characterized by rapid and potentially irreversible visual loss.

Observation:

An 18-year-old male presented with headaches and visual obscurations, rapidly progressing to severe bilateral optic disc swelling.
Brain MRI/MRV excluded mass lesions and cerebral venous thrombosis; lumbar puncture revealed markedly elevated intracranial pressure.

Findings:

Urgent bilateral optic nerve fenestration was performed due to the fulminant presentation.
The patient experienced improved vision in both eyes post-procedure.

Implications:

This case underscores the critical importance of promptly recognizing fulminant intracranial hypertension.
Immediate surgical intervention, such as optic nerve fenestration, is crucial to prevent profound visual loss and blindness.